Welcome to the Kids' Library!

The 15-ounce pound : big pharma's plan to patent pot

Pietri, Joseph R., author.
Walterville, Oregon : Trine Day LLC, [2014] 2014

The antibiotic era : reform, resistance, and the pursuit of a rational therapeutics

Podolsky, Scott H., author.
Baltimore, Maryland : Johns Hopkins University Press, 2015. 2015

Authorized generic drugs short-term effects and long-term impact.

United States. Federal Trade Commission.
[Washington, D.C.] : Federal Trade Commission, [2011] 2011

Avoiding conflicts of interest at the National Institutes of Health : hearing before a subcommittee

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2004. 2004

Building resilient supply chains, revitalizing American manufacturing, and fostering broad-based gro

Washington : The White House, 2021. 2021

Competition in prescription drug markets, 2017-2022

Parasrampuria, Sonal, author.
[Washington, D.C.] : Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services, 2023. 2023

Competition in the pharmaceutical marketplace : antitrust implications of patent settlements : heari

United States. Congress. Senate. Committee on the Judiciary.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., [Congressional Sales Office], 2002. 2002

The competitive status of the U.S. pharmaceutical industry the influences of technology in determini

National Academy of Engineering. Committee on Technology and International Economic and Trade Issues. Pharmaceutical Panel.
Washington, D.C. ; [Great Britain] : National Academy Press, 1983. 1983

COVID-19 : international trade and access to pharmaceutical products

Hart, Nina M., author.
[Washington, D.C.] : Congressional Research Service, 2020- 2020

Creating and Restoring Equal Access to Equivalent Samples Act of 2019 : report (to accompany H.R. 96

United States. Congress. House. Committee on Energy and Commerce, author.
[Washington, D.C.] : [U.S. Government Publishing Office], [2019]- 2019

The cult of pharmacology how America became the world's most troubled drug culture

DeGrandpre, Richard J.
Durham : Duke University Press, 2006. 2008

Drug pricing manufacturer discounts in the 340B program offer benefits, but federal oversight needs

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Govt. Accountability Office, [2011] 2011

Drug shortage crisis : lives are in the balance : hearing before the Subcommittee on Health Care, Di

United States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Health Care, District of Columbia, Census, and the National Archives.
Washington : U.S. G.P.O. : for sale by the Supt. of Docs., U.S. G.P.O., 2012. 2012

Drug shortages, certain factors are strongly associated with this persistent public health challenge

United States. Government Accountability Office, author.
[Washington, D.C.] : United States Government Accountability Office, 2016. 2016

Drug shortages, public health threat continues, despite efforts to help ensure product availability

United States. Government Accountability Office, issuing body.
[Washington, D.C.] : United States Government Accountability Office, 2014. 2014

Drug shortages : why they happen and what they mean : hearing before the Committee on Finance, Unite

United States. Congress. Senate. Committee on Finance, author.
Washington : U.S. Government Printing Office, 2011. 2011

Drug truths : dispelling the myths about pharma R&D

LaMattina, John L.
Hoboken, N.J. : John Wiley & Sons, c2009. 2009

Economic analysis of the causes of drug shortages.

Washington, DC : Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, U.S. Department of Health and Human Services, 2011. 2011

The economic aspects of the pharmaceutical industry in the United States : hearing before the Subcom

United States. Congress. House. Committee on Government Reform. Subcommittee on Human Rights and Wellness.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2003. 2003

Economic effects of product liability and other litigation involving the safety and effectiveness of

Garber, Steven.
Santa Monica, Calif. : RAND Institute for Civil Justice, 2013. 2013

Economic effects of product liability and other litigation involving the safety and effectiveness of

Garber, Steven.
Santa Monica, Calif. : RAND Institute for Civil Justice, 2013. 2013

Electronic drug labeling no consensus on the advantages and disadvantages of its exclusive use : rep

United States. Government Accountability Office, issuing body.
[Washington, D.C.] : United States Government Accountability Office, 2013. 2013

Entry threats and pricing in the generic drug industry

Wendling, Brett.
Washington, DC : Bureau of Economics, Federal Trade Commission, [2010] 2010

Experiences of health maintenance organizations with pharmacy benefit management companies.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 1997. 1998

FDA and the drug development process how the agency ensures that drugs are safe and effective.

Rockville, MD : Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, [2002] 2002

FDA-approved bargain drugs generic products must meet high standards.

Rockville, MD : Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, [2003] 2003

The federal role in addressing the Adderall drug shortage

Sacco, Lisa N., author.
[Washington, D.C.] : Congressional Research Service, 2023- 2023

Food and Drug Administration effect of user fees on drug approval times, withdrawals, and other agen

United States. General Accounting Office.
[Washington, D.C.] : U.S. General Accounting Office, [2002] 2002

Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Commi

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008. 2008

Generic drug industry dynamics

Reiffen, David A.
[Washington, D.C. : Bureau of Economics, U.S. Federal Trade Commission, 2002] 2002

The generic drug maze : speeding access to affordable life-saving drugs : hearing before the Special

United States. Congress. Senate. Special Committee on Aging.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2006. 2006

Generic drugs the pay-for-delay problem

New York : Nova Biomedical/Nova Science Publishers, c2011. 2011

Generic pharmaceuticals : marketplace access and consumer issues : hearing before the Committee on C

United States. Congress. Senate. Committee on Commerce, Science, and Transportation.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2004. 2004

How health care reform affects pharmaceutical research and development

Cook, Anna (Anna E.)
Washington, D.C. : Congressional Budget Office, [1994] 1994

International trade and pharmaceuticals : joint hearing before the Subcommittee on International Tra

United States. Congress. Senate. Committee on Finance. Subcommittee on International Trade.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2004. 2004

Liability issues related to COVID-19 vaccine manufacturing and global distribution

Tharakan, Sara M., author.
[Washington, D.C.] : Congressional Research Service, 2021- 2021

Measuring prescription drug prices : a primer on the CPI Prescription Drug Index

Council of Economic Advisers (U.S.), author.
[Washington, D.C.] : Executive Office of the President of the United States, Council of Economic Advisers, 2019. 2019

Money talks profits before patient safety.

[Milwaukee, Wis.] : Hummingbird Pictures, c2006. 2006

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 : report (to a

United States. Congress. House. Committee on Energy and Commerce, author.
[Washington, D.C.] : [U.S. Government Publishing Office], [2020] 2020

Orange Book Transparency Act of 2019 : report (to accompany H.R. 1503) (including cost estimate of t

United States. Congress. House. Committee on Energy and Commerce, author.
[Washington, D.C.] : [U.S. Government Publishing Office], [2019] 2019

Overdo$ed America : the broken promise of American medicine

Abramson, John.
New York, N.Y. : HarperCollins Publishers, c2004. 2004

Patents and regulatory exclusivities: issues in pharmaceutical innovation and competition

Thomas, John R., 1967- author.
[Washington, D.C.] : Congressional Research Service, [2018?]- 2018

Paying off generics to prevent competition with brand name drugs : should it be prohibited? : hearin

United States. Congress. Senate. Committee on the Judiciary.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2007. 2007

Permitting genetically engineered plants that produce pharmaceutical compounds

Riverdale, MD : Biotechnology Regulatory Services, U.S. Dept. of Agriculture, Animal and Plant Health Inspection Service, [2006] 2006

Perspectives of drug manufacturers : abbreviated new drug applications.

United States. Department of Health and Human Services. Office of Inspector General. Office of Evaluation and Inspections, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, Office of Evaluation and Inspections, 1990. 1990

Perspectives of drug manufacturers : investigational new drug and new drug applications.

United States. Department of Health and Human Services. Office of Inspector General. Office of Evaluation and Inspections, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, Office of Evaluation and Inspections, 1990. 1990

Pharma : greed, lies, and the poisoning of America

Posner, Gerald L., author.
New York : Avid Reader Press, 2020. 2020